Investor Relations / Events

Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual meeting

May 4, 2025 
- May 8, 2025

Cognition reported preclinical data at the 2025 Association for Research in Vision and Ophthalmology (ARVO) congress showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD).

Posters:

  • Sigma-2 Receptor Modulation Promotes Retinal Pigmented Epithelial Cell Survival Following Chronic 7-Ketocholesterol Exposure (view poster here)
  • Delineating Mechanisms of Sigma-2 Receptor Modulators in Regulating Retinal Pigmented Epithelial Lipid Uptake (view poster here)
View All Events

Investor Relations Contact

Cognition Therapeutics
info@cogrx.com

Mikey Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Email Alerts

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.brightfocus.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.preventblindness.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to https://lewybodyresourcecenter.org/

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.lbda.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.alz.org